key: cord-0915446-04li1h2m authors: Senefeld, Jonathon W.; Casadevall, Arturo; Joyner, Michael J. title: Convalescent plasma to deliver therapeutic antibodies against COVID-19 date: 2022-02-21 journal: Trends Mol Med DOI: 10.1016/j.molmed.2022.02.005 sha: 6937adfd827c9381b633622d6bfeca2854291202 doc_id: 915446 cord_uid: 04li1h2m nan  The immunological profile of CP contains a wide distribution of antibody isotypes and subclasses raising concerns about standardization, optimal dosing, and potency.  Several aspects of the antibody profile are not fully understood, including assay systems to determine antibody profile and therapeutic target levels to confer protective immunity.  Recruitment and screening of potential CP donors pose logistical and regulatory challenges.  Potential adverse events of CP therapy include known risks associated with transfer of blood substances and theoretical risk of antibody-dependent enhancement of infection.  Transfusion of CP with high titer, functional antibodies early in COVID-19 disease course may reduce hospitalizations and risk of death.  Widespread access to CP for novel infectious diseases is feasible and was authorized by US FDA during the COVID-19 pandemic, via expanded access program i,ii and subsequent emergency use authorization iii,iv,v .  CP should be considered as a potential treatment in future infectious disease outbreaks. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors Convalescent plasma for infectious diseases: historical framework and use in COVID-19 Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study 2021) mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 The figures were generated with Biorender.com No interests are declared.